Evidence map›Paper›PMID 26044963›Full record

ArticleJournal of the neurological sciences2015

Optimal combination treatment and vascular outcomes in recent ischemic stroke patients by premorbid risk level.

Jong-Ho Park, Bruce Ovbiagele

Abstract read
In one paragraph

Article in Journal of the neurological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Jong-Ho ParkDepartment of Neurology, Seonam University Myongji Hospital, Goyang, South Korea; Department of Neurology, Medical University of South Carolina, Charleston, SC, United States.
Bruce OvbiageleDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States. Electronic address: Ovibes@musc.edu.
Medical University of South Carolina · USMyongji Hospital · KR

Funding

Tailored Hospital-based Risk Reduction to Impede Vascular Events after Stroke (THU01NS079179 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OVBIAGELE, BRUCE · 2012 to 2016
$2.1M
NINDS NIH HHS U01 NS079179
6 · The paper itself

Abstract

backgroundOptimal combination of secondary stroke prevention treatment including antihypertensives, antithrombotic agents, and lipid modifiers is associated with reduced recurrent vascular risk including stroke. It is unclear whether optimal combination treatment has a differential impact on stroke patients based on level of vascular risk.

methodsWe analyzed a clinical trial dataset comprising 3680 recent non-cardioembolic stroke patients aged ≥35 years and followed for 2 years. Patients were categorized by appropriateness levels 0 to III depending on the number of the drugs prescribed divided by the number of drugs potentially indicated for each patient (0=none of the indicated medications prescribed and III=all indicated medications prescribed [optimal combination treatment]). High-risk was defined as having a history of stroke or coronary heart disease (CHD) prior to the index stroke event. Independent associations of medication appropriateness level with a major vascular event (stroke, CHD, or vascular death), ischemic stroke, and all-cause death were analyzed.

resultsCompared with level 0, for major vascular events, the HR of level III in the low-risk group was 0.51 (95% CI: 0.20-1.28) and 0.32 (0.14-0.70) in the high-risk group; for stroke, the HR of level III in the low-risk group was 0.54 (0.16-1.77) and 0.25 (0.08-0.85) in the high-risk group; and for all-cause death, the HR of level III in the low-risk group was 0.66 (0.09-5.00) and 0.22 (0.06-0.78) in the high-risk group.

conclusionOptimal combination treatment is related to a significantly lower risk of future vascular events and death among high-risk patients after a recent non-cardioembolic stroke.

Indexed as

AdultAgedAntihypertensive AgentsBrain IschemiaCombined Modality TherapyCoronary Artery DiseaseFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedRecurrenceSecondary PreventionStrokeAntihypertensive AgentsFibrinolytic AgentsDeathDrugHigh-riskSecondary preventionStrokeVascular events

Identifiers

PMID26044963
PMCPMC4492833
OpenAlexW1558164530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.